Indole and trans-chalcone attenuate amyloid β plaque accumulation in male wistar rat: In vivo effectiveness of two anti-amyloid scaffolds

Archives Italiennes de Biologie

Volumn 151, Issue 3, 2013, Pages 106-113

  Yaghmaei, P ^a   Kheirbakhsh, R ^a   Dezfulian, M ^b   Haeri Rohani, A ^c   Larijani, B ^d   Ebrahim Habibi, A ^d  

^a ISLAMIC AZAD UNIVERSITY   (Iran)

^b ISLAMIC AZAD UNIVERSITY   (Iran)

^c UNIVERSITY OF TEHRAN   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Alzheimer; Beta amyloid; Indole; Trans chalcone; Wistar rat

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN (1 42); AMYLOID BETA-PROTEIN (1-42); CHALCONE; INDOLE; INDOLE DERIVATIVE; NEUROLEPTIC AGENT; PEPTIDE FRAGMENT;

AMYLOID PLAQUE; ANIMAL; ARTICLE; AVOIDANCE BEHAVIOR; CHEMICALLY INDUCED DISORDER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECT; FRONTAL LOBE; HIPPOCAMPAL CA1 REGION; MALE; METABOLISM; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; RAT; TIME; WISTAR RAT;

AMYLOID BETA-PEPTIDES; ANIMALS; ANTIPSYCHOTIC AGENTS; AVOIDANCE LEARNING; CA1 REGION, HIPPOCAMPAL; CHALCONE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FRONTAL LOBE; INDOLES; MALE; PEPTIDE FRAGMENTS; PLAQUE, AMYLOID; RATS; RATS, WISTAR; TIME FACTORS;

EID: 84897803318     PISSN: 00039829     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Ateş-Alagöz Z., Coban T., Sibel S.L. A comparative study: Evaluation of antioxidant activity of melatonin and some indole derivatives. Med. Chem. Res., 14: 169-179, 2005.
2. Bendheim P.E., Poeggeler B., Neria E., Ziv V., Pappolla M.A., Chain D.G. Development of indole-3-propionic acid (OXIGON) for alzheimer's disease. J. Mol. Neurosci., 19: 213-217, 2002.
3. Cetin, F. and Dincer S,. The Effect of Intrahippocampal Beta Amyloid (1-42) Peptide Injection on Oxidant and Antioxidant Status in Rat Brain. Ann. NY Acad. Sci., 1100: 510-517, 2007.
4. Chyan Y.J., Poeggeler B., Omar R.A., Chain D.G., Frangione B., Ghiso J., Pappolla M.A. Potent neuroprotective properties against the Alzheimer beta-amyloid by an endogenous melatonin-related indole structure, indole-3-propionic acid. J. Biol. Chem., 274: 21937-21942, 1999.
5. Craggs L. and Kalaria R.N,. Revisiting dietary antioxidants, neurodegeneration and dementia. Neuroreport, 22: 1-3, 2011.
6. Davies P. and Koppel J,. Mechanism-based treatments for Alzheimer's disease. Dialogues Clin. Neurosci., 11: 159-169, 2009.
7. Davinelli S., Sapere N., Zella D., Bracale R., Intrieri M., Scapagnini G. Pleiotropic protective effects of phytochemicals in Alzheimer's disease. Oxid. Med. Cell. Longev., 386527, 2012.
8. de la Torre J.C. Alzheimer's disease is incurable but preventable. J. Alzheimers Dis., 20: 861-870, 2010.
9. Ferrer J.L., Austin M.B., Stewart C. Jr., Noel J.P. Structure and function of enzymes involved in the biosynthesis of phenylpropanoids. Plant. Physiol. Biochem., 46: 356-370, 2008.
10. Frautschy S.A., Baird A., Cole G.M. Effects of injected Alzheimer beta-amyloid cores in rat brain. Proc. Natl. Acad. Sci. USA, 88:8362-6, 1991.
11. Gandy S. The role of cerebral amyloid beta accumulation in common forms of Alzheimer disease. J. Clin. Invest., 115: 1121-1129, 2005.
12. Guaza C. and Borrell J,. Prolonged ethanol consumption influences shuttle box and passive avoidance performance in rats. Physiol. Behav., 34: 163-165, 1985.
13. Jagota S. and Rajadas J,. Effect of phenolic compounds against Abeta aggregation and Abeta-induced toxicity in transgenic C. elegans. Neurochem. Res., 37: 40-48, 2012.
14. Joachim C.L. and Selkoe D.J,. The seminal role of beta-amyloid in the pathogenesis of Alzheimer disease. Alzheimer Dis. Assoc. Disord., 6: 7-34, 1992.
15. Lamoke F., Labazi M., Montemari A., Parisi G., Varano M., Bartoli M. Trans-Chalcone prevents VEGF expression and retinal neovascularization in the ischemic retina. Exp. Eye Res., 93: 350-354, 2011.
16. Lipton S.A. Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. Nat. Rev. Drug Discov., 5: 160-170, 2006.
17. Lorenzo A. and Yankner B.A,. Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. Proc. Natl. Acad. Sci. USA, 91: 12243-12247, 1994.
18. Medeiros R., Prediger R.D., Passos G.F., Pandolfo P., Duarte F.S., Franco J.L., Dafre A.L., Di Giunta G., Figueiredo C.P., Takahashi R.N., Campos M.M., Calixto J.B. Connecting TNF-alpha signaling pathways to iNOS expression in a mouse model of Alzheimer's disease: relevance for the behavioral and synaptic deficits induced by amyloid beta protein. J. Neurosci., 27: 5394-5404, 2007.
19. Mohamed T. and Rao P.P.N,. Alzheimers disease: emerging trends in small molecule therapies. Curr. Med. Chem., 18: 4299-4320, 2011.
20. Mohareb R.M., Ahmed H.H., Elmegeed G.A., Abd- Elhalim M.M., Shafic R.W. Development of new indole-derived neuroprotective agents. Bioorg. Med. Chem., 19: 2966-2974, 2011.
21. Morshedi D., Rezaei-Ghaleh N., Ebrahim-Habibi A., Ahmadian S., Nemat-Gorgani M. Inhibition of amyloid fibrillation of lysozyme by indole derivatives: possible mechanism of action. FEBS J., 274: 6415-6425, 2007.
22. Najafian M., Ebrahim-Habibi A., Yaghmaei P., Parivar K., Larijani B. Core structure of flavonoids precursor as an antihyperglycemic and antihyperlipidemic agent: an in vivo study in rats. Acta Biochim. Pol., 57: 553, 2010.
23. O'Hare E., Weldon D.T., Mantyh P.W., Ghilardi J.R., Finke M.P., Kuskowski M.A., Maggio J.E., Shephard R.A., Cleary J. Delayed behavioral effects following intrahippocampal injection of aggregated Abeta 1-42. Brain Res., 815: 1-10, 1999.
24. Ono K., Li L., Takamura Y., Yoshiike Y., Zhu L., Han F., Mao X., Ikeda T., Takasaki J., Nishijo H., Takashima A., Teplow D.B., Zagorski M.G., Yamada M. Phenolic compounds prevent amyloid beta-protein oligomerization and synaptic dysfunction by site-specific binding. J. Biol. Chem., 287: 14631-14643, 2012.
25. Pappolla M.A., Simovich M.J., Bryant-Thomas T., Chyan Y.J., Poeggeler B., Dubocovich M., Bick R., Perry G., Cruz-Sanchez F., Smith M.A. The neuroprotective activities of melatonin against the Alzheimer beta-protein are not mediated by melatonin membrane receptors. J. Pineal Res., 32: 135-142, 2002.
26. Pappolla M.A., Sos M., Omar R.A., Bick R.J., Hickson-Bick D.L., Reiter R.J., Efthimiopoulos S., Robakis N.K. Melatonin prevents death of neuroblastoma cells exposed to the Alzheimer amyloid peptide. J. Neurosci., 17: 1683-1690, 1997.
27. th Edition, Academic Press, 2007.
28. Piñero J., Temporal R.M., Silva-Gonçalves A.J., Jiménez I.A., Bazzocchi I.L., Oliva A., Perera A., Leon L.L., Valladares B. New administration model of trans-chalcone biodegradable polymers for the treatment of experimental leishmaniasis. Acta Trop., 98 59-65, 2006.
29. Polvikoski T., Sulkava R., Haltia M., Kainulainen K., Vuorio A., Verkkoniemi A., Niinistö L., Halonen P., Kontula K. Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein. N. Engl. J. Med., 333: 1242-1247, 1995.
30. Povova J., Ambroz P., Bar M., Pavukova V., Sery O., Tomaskova H., Janout V. Epidemiological of and risk factors for Alzheimer's disease: a review. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub., 156: 108-114, 2012.
31. Praticò D., Uryu K., Leight S., Trojanoswki J.Q., Lee V.M. Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J. Neurosci., 21: 4183- 4187, 2001.
32. Recanatini M. and Valenti P,. Acetylcholinesterase inhibitors as a starting point towards improved Alzheimer's disease therapeutics. Curr. Pharm. Des., 10: 3157-3166, 2004.
33. Reitz C. Alzheimer's disease and the amyloid cascade hypothesis: a critical review. Int. J. Alzheimers. Dis., 369808, 2012.
34. Rubio-Perez J.M. and Morillas-Ruiz J.M,. A review: inflammatory process in Alzheimer's disease, role of cytokines. ScientificWorldJournal 756357, 2012.
35. Sheikh I.A., Ali R., Dar T.A., Kamal M.A. An overview on potential neuroprotective compounds for management of Alzheimer's disease. CNS Neurol. Disord. Drug Targets, 11: 1006-1011, 2012.
36. Sikander M., Malik S., Yadav D., Biswas S., Katare D.P., Jain S.K. Cytoprotective activity of a transchalcone against hydrogen peroxide induced toxicity in hepatocellular carcinoma (HepG2) cells. Asian Pac. J. Cancer Prev., 12: 2513-2516, 2011.
37. Sperling R.A., Aisen P.S., Beckett L.A., Bennett D.A., Craft S., Fagan A.M., Iwatsubo T., Jack C.R. Jr, Kaye J., Montine T.J., Park D.C., Reiman E.M., Rowe C.C., Siemers E., Stern Y., Yaffe K., Carrillo M.C., Thies B., Morrison-Bogorad M., Wagster M.V., Phelps C.H,. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging- Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement, 7: 280-292, 2011.
38. Sultana R., Perluigi M., Allan Butterfield D. Lipid peroxidation triggers neurodegeneration: A redox proteomics view into the Alzheimer disease brain. Free Radic. Biol. Med., 62: 157-169, 2012.
39. Török M., Abid M., Mhadgut S.C., Török B. Organofluorine inhibitors of amyloid fibrillogenesis. Biochemistry, 45: 5377-5383, 2006.
40. Uriarte-Pueyo I. and Calvo M.I,. Flavonoids as acetylcholinesterase inhibitors. Curr. Med. Chem., 18: 5289-5302, 2011.
41. Vassar R. Beta-Secretase (BACE) as a drug target for alzheimer's disease. Adv. Drug Deliv. Rev., 54: 1589-1602, 2002.
42. Walker L.C. and LeVine H,. Corruption and spread of pathogenic proteins in neurodegenerative diseases. J. Biol. Chem., 287: 33109-33115, 2012.
43. Wang X.C., Zhang Y.C., Chatterjie N., Grundke- Iqbal I., Iqbal K., Wang J.Z. Effect of melatonin and melatonylvalpromide on beta-amyloid and neurofilaments in N2a cells. Neurochem. Res., 33: 1138-1144, 2008.
44. Williams R.J. and Spencer J.P,. Flavonoids, cognition, and dementia: actions, mechanisms, and potential therapeutic utility for Alzheimer disease. Free Radic. Biol. Med., 52: 35-45, 2012.
45. Wimo A. and Prince M.J,. World Alzheimer Report 2010: the global economic impact of dementia. Alzheimer's Disease International.
46. Yan J.J., Cho J.Y., Kim H.S., Kim K.L., Jung J.S., Huh S.O., Suh H.W., Kim Y.H., Song D.K. Protection against β-amyloid peptide toxicity in vivo with long-term administration of ferulic acid. Br. J. Pharmacol., 133: 89-96, 2001.